
Although widely reported to affect older adults more, coronavirus disease 2019 (COVID-19) also affects adolescents, especially those with co-morbidities, including heart diseases. The safety and efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been established in healthy adolescents. Yet, there are data for humoral and cellular immunogenicity in adolescents with cardiac diseases. This study evaluated anti-spike antibodies, neutralizing activities, and interferon-gamma production before and after SARS-CoV-2 vaccination in adolescents with cardiac conditions and healthy controls. The SARS-CoV-2 mRNA vaccine has efficient immunogenicity for adolescents with CHD, IPAH, and DCM. However, half of the post-HTx patients could not acquire sufficient humoral immunity.
Like
Save
Share